

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

PROPOSED CHANGE OF AUDITOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

RETIREMENT OF AUDITOR

The Board hereby announces that due to the lack of consensus with Ernst & Young (“**EY**”) on the audit fee in respect of the audit of the Group’s consolidated financial statements for the year ending December 31, 2025, the Board proposed that EY will retire as the auditor of the Company at the conclusion of the forthcoming annual general meeting of the Company (the “**Annual General Meeting**”) upon the expiration of its current term of office.

EY has confirmed with the Company that there are no matters relating to its retirement that need to be brought to the attention of the shareholders (the “**Shareholders**”) or the creditors of the Company. The Board and the audit committee of the Board (the “**Audit Committee**”) also confirmed that there was no disagreement between the Company and EY or other matters relating to the proposed change of auditor that need to be brought to the attention of the Shareholders or the creditors of the Company.

The Board would like to take this opportunity to express its gratitude to EY for the professional services it has provided to the Group during its tenure of service.

PROPOSED APPOINTMENT OF NEW AUDITOR

The Audit Committee, having reviewed the credentials of CL Partners CPA Limited (“**CL Partners**”), including its qualification and experience, considers that CL Partners possesses the essential audit experience to perform its duties as the auditor of the Company.

The Board hereby announces that, with the recommendation from the Audit Committee, the Board has proposed to appoint CL Partners as new auditor of the Company following the retirement of EY with effect from the conclusion of the forthcoming Annual General Meeting and until the conclusion of the next annual general meeting of the Company, subject to the approval by the Shareholders at the forthcoming Annual General Meeting.

The proposed appointment of CL Partners as the auditor of the Company will be put forward for approval by the Shareholders by way of an ordinary resolution at the forthcoming Annual General Meeting.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, May 19, 2025

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.